• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • Microbial limits for non-sterile chemical drugs, API and excipients – new guidelines issued

Microbial limits for non-sterile chemical drugs, API and excipients – new guidelines issued

Microbial limits for non-sterile chemical drugs
Thursday, 30 March 2023 / Published in News, NMPA Registration in China, Pharmaceuticals & DMF

Microbial limits for non-sterile chemical drugs, API and excipients – new guidelines issued

Microbial limits for non-sterile chemical drugs, active pharmaceutical ingredients (API) and excipients were released in a new set of guidelines (trial) by China’s Center for Drug Evaluation (CDE) on February 17, 2023. These guidelines are intended to serve as a reference for pharmaceutical companies and industry peers.

The main objective of these guidelines is to enhance the application of quality risk management in product quality control and improve the scientific and rational development of microbial limit standards for non-sterile chemical drugs and raw and auxiliary materials. Several problems were discovered with the current declaration process for non-sterile chemicals, raw and auxiliary materials hence the reason for developing these trial guidelines:

  • The first issue is that there is no study of microbial limits in the declaration information and no risk assessment. This means that pharmaceutical companies are not adequately assessing the risks associated with microbial limits and may be missing potential issues with their products.
  • The second problem is that the content related to microbial limit testing reflected in the declaration information is not standardized and perfect. This can lead to inconsistencies in testing methods and limit settings, making it difficult to compare results between different products.
  • The third issue is that the source of strains and testing methods in the declaration of imported drug registration information is problematic. This means that the data presented in these declarations may not be reliable or accurate, which can have serious consequences for product safety and efficacy.

To address these issues and the uncertain impact they have on drug technical and quality reviews, China’s Center for Drug Evaluation has issued guidelines to guide pharmaceutical companies in standardizing microbial limits for research.

The guidelines provide detailed information on control strategies for:

  • microbial limit studies of non-sterile chemicals, raw materials and excipients,
  • selection of detection methods and limit setting,
  • and production process control.

They also clarify the requirements for microbial limit declaration information, including:

  • microbial limit detection methods,
  • method applicability test information,
  • microbial limit control strategy,
  • and the basis for development.

This information should be included in the declaration information and corresponds to chapters 3.2.S.4 and 3.2.P.5 on the development of analytical methods, validation of analytical methods, and the basis for the development of quality standards. In these chapters, studies are to be conducted in full accordance with the requirements of this guideline.

Further information

Read the original CDE’s announcement (No.11-2023) on the release of technical review guidelines (trial) for microbial limits on non-sterile chemical drugs and active pharmaceutical ingredients.

Our services are designed to help you navigate complex regulations and guidelines, ensuring that your products are safe, effective, and compliant with industry standards. We offer a wide range of services, including regulatory submissions, compliance consulting, quality assurance, and more.

Contact us today to learn more about our services and how we can help your pharmaceutical company succeed.

GET IN TOUCH

🌐 Send us your enquiry
📚 Request our whitepapers
📣 Sign up for our newsletter

What you can read next

Drug-device combination products in 2021: List of Classification Results for the first batch
Unique Identification System (UDI) of Medical Devices
2019 Annual Report, Strengthening Scheme and Updates on Medical Device Mandatory Standards

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • Submission of safety information for cosmetics ingredients

    Submission of safety information for cosmetics raw materials – Draft guidelines issued

    Submission of safety information for cosmetics ...
  • avoid animal testing in Chinaweb-2023

    How to avoid animal testing in China for cosmetics | Cisema Webinar

    China’s beauty and cosmetic market has be...
  • guidelines for medical devices registration

    Guidelines for medical devices registration in China – New development plans in 2023

    Guidelines for medical devices registration in ...
  • China DMF of API

    China DMF of API, Excipient & Packaging Materials: Market & Regulatory | Cisema Webinar

    “China DMF of API, Excipient & Packag...
  • pre-phase III drug clinical trial meeting guidelines

    Pre-phase III drug clinical trial meeting guidelines released

    Pre-phase III drug clinical trial meeting guide...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP